Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial - Sezer, A; Kilickap, S; Gumus, M (Lancet, 2021)
et al.